Cystic fibrosis (CF) is characterised by abnormal ion transport across epithelia."2 This results in profound changes in fluid secretion and absorption in various tissues. In most patients with cystic fibrosis cystic fibrosis transmembrane conductance regulator (CFTR), a chloride channel protein, is not expressed in the apical membrane. This leads to defective cAMP mediated chloride (Cl-) secretion. Air- way epithelium also shows enhanced sodium (Na+) absorption23 which contributes to the dehydration of airway secretions. Ineffective ciliary action leads to the accumulation ofviscid secretions in the lumen of airways, predisposing to endobronchial infection and limiting the effect of host defence mechanisms and antibiotics.
As there is little net movement of chloride ions in the normal human airway,4 pharmacological approaches to activate chloride secretion via CFTR may be unsuccessful. An alternative approach is to maintain the hydration of secreted mucus by blocking the reabsorption of water and sodium ions into the airway epithelial cell. This effect has already been demonstrated both in vivo and in vitro using the sodium channel blocker amiloride,5-7 although other investigators have found the clinical response to inhaled amiloride limited. 8 The therapeutic effect of amiloride may be limited by its relatively short duration of action (half life approximately six hours). Loperamide, which has similar action in the bowel of patients with cystic fibrosis9 and a more prolonged half life of 11 hours, may also be beneficial in this disease.
In cystic fibrosis the nasal PD is increased mainly as a result of enhanced absorption of sodium ions.'01' Thus, the effects of drugs which alter the transport of sodium ions can be assessed by measuring the change in nasal PD after drug administration.'2 Mouse models of cystic fibrosis are now available which share many of the electrophysiological properties with human airways.'3-'" We have examined the effect of the inhaled Na+ channel inhibitors, amiloride and loperamide, on the nasal epithelium of control (MF1) and CF mice.
Methods

EXPERIMENTAL ANIMALS
Twenty CF mice were studied and 14 standard laboratory MF 1 strain mice (Harlan, UK) were used as controls. Both sexes were matched for age (range 3-14 months) and weight (27-52 g ). The animals were allowed food and water ad libitum. The CF mice were developed at Edinburgh'4 and were homozygous for the exon 10 insertional mutation. The breeding was subsidised by the Association Francaise de Lutte contre la Mucoviscidose, France and supplied by Charles River, UK.
A project licence approval was obtained from the Home Office to carry out the procedures. The nasal potential difference was measured between a 24 G exploring catheter filled with 0.1 M KCl/2% agar and a Teflon reference cannula inserted subcutaneously and perfused at 0.5 ml/hour with 0.9% saline through a syringe pump (Perfusor Secura B Braun). The two electrodes were connected to calomel half cells (Russell) by salt-agar bridges containing 1 M KCl/2% agar. Measurements were performed using a high impedance voltmeter (Keithley Instruments Model 602) and recorded with a Bio-Rad chart recorder. Reproducibility was assessed by recording basal PD measurements from both nostrils in five control mice; all the differences were between 1 and 2 mV. Mice were anaesthetised by intraperitoneal injection using a combination of fentanyl (0.6 mg/kg), fluanisone (20 mg/kg), and midazolam (8 mg/kg). Baseline nasal PD was then measured and the maximum reading recorded.
DATA ANALYSIS
The Mann-Whitney U test was used to assess significance between groups and the Wilcoxon signed rank test to assess significance within the groups. Results Significant differences were found between the CF mice and controls for baseline PD and the changes in PD values for both drugs (table 1, p<0.01). The median changes in PD seen in CF mice after the drugs were administered consecutively were -18 mV for amiloride (range -13 to -25) and -17 mV for loperamide (range -13 to -24) (NS, n=11). As loperamide failed to produce any further change in PD, this suggests that it may act via similar mechanisms since the Na+ channels are already maximally inhibited by amiloride. Figures 1 and 2 show the responses to increasing doses of drug. The maximum changes PROTOCOLS Drugs were administered by inhalation over two minutes after removal of the nasal electrode. The nebulisation was achieved using a Medic-aid compressor with an Acorn system 22 nebuliser attached to a mask. The mask was occluded with parafilm and a hole made so that it fitted over the mouth and nostrils of the mice. Measurements were restarted promptly after nebulisation with the recording electrode resited in the nostril at the same depth. After each experiment the mice were allowed to recover from the anaesthetic so that the procedure could be repeated at a later date. The effect of nebulised amiloride (1 mmol/l dissolved in water, Sigma, UK) was compared with nebulised loperamide (1 mmol/l dissolved in water, a gift from Janssen Pharmaceuticals, Beerse, Belgium) given over a similar period. Changes in PD were measured after equimolar solutions (1 mmol/l) of amiloride and loperamide were administered consecutively. To assess the response to increasing drug doses, amiloride in doses of 0.1, 0.2, 0.5, 1.0, and 3.0 mmol/l and loperamide in doses of 0.1, 0.2, 0.3, 0.5, and 1.0 mmol/l were given sequentially and the PD changes recorded. In this experiment the PD changes were allowed to stabilise before the next higher concentration was given. The duration of action of the drugs was also studied after a standard single dose of both agents
(1 mmol/l). The changes in PD were measured at baseline, immediately after nebulisation, and then every two hours for eight hours. Sodium uptake into nasal epithelia is regulated mainly by the amiloride sensitive sodium channel20 which is a transmembrane protein consisting of three homologous subunits2122 present in many tissues23 of various species. Studies using human nasal epithelium in the form of cell attached patches have shown that there is a small proportion (<6%) of nonselective cation channels involved in sodium transport" which cannot be blocked by am- iloride. The amiloride sensitive sodium channel appears to be relatively specific and is un-6 8 affected by amiloride analogues which have less specificity for the sodium channel. 24 The effect ofloperamide is probably produced by a similar ential action on the amiloride sensitive sodium chanlation of nel since the effect of loperamide was absent CF mice after maximal inhibition of the sodium channel by pretreatment with amiloride. In addition to blocking apical sodium absorption, amiloride has been shown to induce at about chloride secretion in airway tissue by hypermice. Al-polarising the apical membrane and genrved with erating a driving force for secretion of chloride en 0.5 and ions. However, secretion of chloride ions is ), but this absent in subjects with cystic fibrosis and the mice. 
